VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Bekaii-Saab on the Potential Impact of Napabucasin Combo in Pancreatic Cancer

Tanios Bekaii-Saab, MD
Published: Wednesday, Jul 12, 2017



Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the potential impact of the combination of napabucasin with gemcitabine and nab-paclitaxel in pancreatic cancer.

Bekaii-Saab says the big takeaways from the phase II study of napabucasin with gemcitabine and nab-paclitaxel is that it is a safe regimen, and given the lack of standard of care in pancreatic cancer, this is an opportunity to improve upon the activity of an established regimen.
 


Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the potential impact of the combination of napabucasin with gemcitabine and nab-paclitaxel in pancreatic cancer.

Bekaii-Saab says the big takeaways from the phase II study of napabucasin with gemcitabine and nab-paclitaxel is that it is a safe regimen, and given the lack of standard of care in pancreatic cancer, this is an opportunity to improve upon the activity of an established regimen.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High CancersAug 29, 20182.0
Community Practice Connections™: 1st Annual School of Nursing Oncology™Oct 31, 20181.5
Publication Bottom Border
Border Publication
x